Telesis Bio is a medical devices business based in the US. Telesis Bio shares (TBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Telesis Bio employs 127 staff and has a trailing 12-month revenue of around $24.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.12 |
|---|---|
| 52-week range | $3.03 - $29.34 |
| 50-day moving average | $3.89 |
| 200-day moving average | $7.07 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-28.29 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.12 from 2024-07-22
| 1 week (2024-07-17) | 5.91% |
|---|---|
| 1 month (2024-06-24) | 11.05% |
| 3 months (2024-04-24) | 1,182.29% |
| 6 months (2024-01-24) | 951.02% |
| 1 year (2023-07-24) | 200.73% |
|---|---|
| 2 years (2022-07-20) | N/A |
| 3 years (2021-07-23) | 30 |
| 5 years (2019-07-24) | 8.9 |
| Revenue TTM | $24.6 million |
|---|---|
| Gross profit TTM | $15.6 million |
| Return on assets TTM | -26.81% |
| Return on equity TTM | -155.29% |
| Profit margin | -183.66% |
| Book value | $-4.93 |
| Market Capitalization | $6.7 million |
TTM: trailing 12 months
We're not expecting Telesis Bio to pay a dividend over the next 12 months.
Telesis Bio's shares were split on a 1:18 basis on 8 May 2024. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Telesis Bio shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Telesis Bio shares which in turn could have impacted Telesis Bio's share price.
Over the last 12 months, Telesis Bio's shares have ranged in value from as little as $3.025 up to $29.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Telesis Bio's is 1.743. This would suggest that Telesis Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Telesis Bio, Inc. , a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.